As we know, early detection of cancer significantly increases the chances of successful treatment. One of the groundbreaking methods in this realm is plasma DNA cancer testing, a non-invasive procedure that can detect the presence of certain cancers at their earliest stages. In this article, we will delve into the specifics of plasma DNA cancer testing, its importance, and how it is performed. We will also highlight some of the leading solutions in this domain, provided by Wuhan Ammunition Life-tech Co., Ltd (WALT), a top-tier Chinese manufacturer and supplier specializing in non-invasive detection products for high-incidence malignant tumors.
What is Plasma DNA Cancer Testing?
Plasma DNA testing, also referred to as a “liquid biopsy”, is a method that detects cancerous mutations in DNA fragments circulating in the blood. These fragments, often referred to as circulating tumor DNA (ctDNA), can provide valuable information about the presence and progression of cancer, even before symptoms appear.
The Role of WALT in Plasma DNA Cancer Testing
Wuhan Ammunition Life-tech Co., Ltd (WALT), a high-tech enterprise established in January 2015, has been pioneering the field of early non-invasive detection products for high-incidence malignant tumors. Their innovative approach combines epigenetics, bioinformatics, clinical big data, and artificial intelligence to create a new generation of tumor screening and detection technology platform.
WALT has launched a series of detection products for high-incidence cancers, including but not limited to digestive system tumors, gynecological tumors, urinary system tumors, and pan-cancer. These cutting-edge diagnostic products are designed to potentially save billions of lives worldwide by enabling early detection of various types of cancer.
ICervsure
The ICervsure kit, for instance, offers a non-invasive method for early detection of cervical cancer, one of the most common cancers among women globally.
IColocomf
Another product, IColocomf, is a non-invasive DNA Methylation detection kit for colorectal cancer. It uses unique atomic signal capture techniques to enhance sensitivity for methylation-specific qPCR, offering a more convenient, fast, and precise method for colorectal cancer screening.
IColohunter & IEsohunter
The IColohunter and IEsohunter are other kits in WALT’s portfolio, focusing on the detection of colon cancer and esophageal cancer, respectively.
IHepcomf & IUterusure
The IHepcomf and IUterusure kits are designed for the detection of hepatocellular carcinoma and uterine cancer, respectively.
How is Plasma DNA Cancer Testing Performed?
The process of plasma DNA cancer testing is straightforward and non-invasive. The patient’s blood is drawn and sent to a laboratory for analysis. The lab then extracts the DNA from the plasma and sequences it, looking for specific genetic mutations indicative of certain types of cancer.
For a more detailed explanation of the procedure, you can refer to WALT’s blog, Demystifying Non-Invasive Cancer Detection and How to Perform It.
Conclusion
By making early detection of cancer more accessible and less invasive, companies like WALT are playing a crucial role in the global fight against cancer. As a leading manufacturer and supplier in the B2B domain, WALT offers promising business opportunities for companies looking to provide these life-saving tests.
For more information about WALT and their innovative products, feel free to contact them or visit their official website. Together, we can make strides in early cancer detection and treatment, ultimately saving more lives.